Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and ...

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences ...

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the Hottest Small Cap Stocks to Buy Now. On November 11, Andy Hsieh from ...

Using chronological age cut-offs—such as 60 years—to divide patients with acute myeloid leukemia (AML) for clinical trials ...

Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD ...

This advisory highlights more than 100 poster abstracts that will be presented at ASH 2025 involving researchers ...

Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract Upcoming ASH oral presentation to feature expanded and updated dataset from ...

Ziftomenib (Komzifti) was approved on Thursday for adults with relapsed/refractory NPM1 -mutated AML who have no satisfactory ...

Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, announced the presentation of new data from 14 studies across ...

CNW/ - GSK Canada is pleased to announce that Ojjaara (momelotinib) will now be reimbursed by Régie de l'assurance maladie du ...

Completed enrollment of the randomized Phase 1b cohorts of the ongoing ENABLE trial of ELVN-001 in CML Remains on track to initiate Phase 3 pivotal trial of ELVN-001 ...

Updated clinical development strategy based on positive data In the third quarter of 2025, Mendus shaped up its clinical development plans for the lead program vididencel in myeloid malignancies.The u ...